Home › Free Stock Grades › SPRY
ARS Pharmaceuticals, Inc. (SPRY) Stock Grade
SPRY · Healthcare
D+
Market Cap
$410.1M
P/E Ratio
—
Revenue Growth (YoY)
-5.5%
Net Margin
-203.3%
Return on Equity
—
Dividend Yield
None
About ARS Pharmaceuticals, Inc.'s fundamentals
ARS Pharmaceuticals is a biotechnology company with a market capitalization of $598.8 million that reported a net loss in its latest annual financial statement, resulting in a negative net margin of -203.3%. The company experienced a year-over-year revenue decline of 5.5%, indicating contracting sales during the period. As a pre-profitable biotech firm, ARS does not pay a dividend and lacks meaningful profitability metrics such as P/E ratio and return on equity.